Skip to main content
Equibles

CLLS · Cellectis S.A.

Track CLLS — free

Use CLLS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CLLS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.10 -0.02 (-0.64%) At close · Sep 11
Rebalance outlook locked
Market Cap
$312.23M
Shares
100.72M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.10 Open$3.11 Day$3.01–3.18 52W close$2.60–5.35 Avg vol 30d21K Short int290K · 0.3% float · 17.5d Short vol79% Last earningsMar 20, 2026 DataJan 2020–Sep 2026

Up next

Next earnings call
Sep 18, 2026 Est · unconfirmed · in 1 wks

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+107.5%
Year over year
Operating margin
-45.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+57.1%
Year over year · more shares
Price change (1Y)
+2.3%
Trailing year
Short interest
0.3%
Latest settlement · 17.5 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −15%
below
Price vs 50-day avg +2%
above
RSI (14) 47
neutral
MACD trend Negative
52-week position 18%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −3%
trailing
6-month return −7%
trailing
YTD return −36%
this year
Relative strength −25%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Distributing
-16% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.29% of float · ▼ -4.0% MoM · 17.5 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
27 holders — mid 3-yr range
Squeeze score 48
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 75%
annualized · 1-yr
Max drawdown −51%
past year
ATR 6.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−15% Bearish
Price vs 50-day avg
+2% Bullish
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
18% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Distributing
-16% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.29% of float · ▼ -4.0% MoM · 17.5 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
27 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3 Now $3 · 18% Range high $5
vs 200-day avg -15% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CLLS
Cellectis S.A.
this stock
$312.23M -36.0% — — 0.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
27
% held
9.4%
Net QoQ
-767.5K sh
Top holder
B Group, Inc.
Held Float
View
Held by Funds
Fund positions
5
View
Short & Settlement
Short Interest Falling
Shares short
289.7K
Days to cover
17.5d
Change
-12.0K sh
View
Short Volume
Short vol %
79%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
50
Value
$145
As of
Aug 12, 2026
View
Off-Exchange
Off-exchange %
45.6%
Week of
Aug 3, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 11, 2026
This year
26
View
Earnings & Events
Earnings Calls Upcoming
Next call
Sep 15, 2026
Last call
Sep 11, 2026
View
Investor Relations
Upcoming events
3
View

Performance

5D 20D 120D MTD YTD
CLLS -6.6% -2.5% -7.2% -7.5% -36.0%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -5.5% -0.8% -25.0% -7.1% -48.0%
Key facts CIK 1627281 CUSIP 15117K103 13F (30d) 15 filings 15 filers Visit website Investor relations